Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 10:41 PM
Ignite Modification Date:
2025-12-25 @ 8:11 PM
NCT ID:
NCT02499835
Group ID:
EG002
Title:
Extended Treatment Arm III
Description:
pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
Pembrolizumab: Given IV
pTVG-HP Plasmid DNA Vaccine: Given ID
Deaths Number Affected:
16
Deaths Number At Risk:
None
Serious Number Affected:
4
Serious Number At Risk:
20
Other Number Affected:
19
Other Number At Risk:
20
Study:
NCT02499835
Results Section:
NCT02499835
Adverse Events Module:
NCT02499835